Evidence map›Paper›PMID 42509253›Full record

ArticleLeukemia2026

Systematic profiling of AGO2-associated circRNAs and functional investigation reveal circN4BP2L2 as a survival-promoting regulator in T-ALL.

Monika Drobna-Sledzinska, Alessia Buratin, Eleonora Roncaglia, Alberto Caregari, Ilias Glogovitis, Maria Kosmalska, Xing Zhao, Silvia Bresolin, Enrico Gaffo, Anke Van den Berg and 3 more

Abstract read
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Monika Drobna-Sledzinska *Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.ORCID http://orcid.org/0000-0003-1671-9071
Alessia Buratin *Department of Molecular Medicine, University of Padova, Padova, Italy.
Eleonora RoncagliaDepartment of Biology, University of Padova, Padova, Italy.
Alberto CaregariDepartment of Biology, University of Padova, Padova, Italy.
Ilias GlogovitisDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Maria KosmalskaInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Xing ZhaoDepartment of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Silvia BresolinOnco-Hematology, Stem Cell Transplant and Gene Therapy Laboratory, IRP-Istituto Di Ricerca Pediatrica, Padua, Italy.
Enrico GaffoDepartment of Oncology Surgery and Gastroenterology, University of Padova, Padova, Italy.ORCID http://orcid.org/0000-0001-6338-7677
Anke Van den BergDepartment of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-8894-2638
Joost KluiverDepartment of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0001-7650-2937
Malgorzata DawidowskaInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.ORCID http://orcid.org/0000-0003-3486-6577
Stefania BortoluzziDepartment of Oncology Surgery and Gastroenterology, University of Padova, Padova, Italy. stefania.bortoluzzi@unipd.it.ORCID http://orcid.org/0000-0001-8240-3070

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 2023 #28966
6 · The paper itself

Abstract

Circular RNAs constitute an emerging area of intensive research in cancer. In T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematologic malignancy characterized by clonal proliferation of T-cell precursors, the function of most aberrantly expressed circRNAs is not yet understood. To identify circRNAs acting as miRNA sponges, we performed AGO2 immunoprecipitation and RNA sequencing (AGO2-RIP-seq) in four T-ALL cell lines. Our analysis revealed circRNAs consistently enriched in the AGO2-bound fraction, highlighting a new resource for T-ALL research. Notably, circRNAs were more enriched (7.3%) compared to linear RNAs (3%). For functional investigation, we focused on the most abundant AGO2-bound circRNAs that were also found to be dysregulated in T-ALL patients. Knockdown of circN4BP2L2 revealed its ability to promote cell proliferation and confer resistance to apoptosis in T-ALL cell lines, in addition to modulating key T-ALL pathogenic pathways. Analysis of gene expression of T-ALL patients disclosed peculiar features of T-ALL with high circN4BP2L2 expression. A marked overlap was observed between differentially expressed genes upon knockdown of circN4BP2L2 in vitro and the profiles of circN4BP2L2 stratified T-ALL cases. This work provides new insights into the circRNA-mediated regulatory networks driving this malignancy and presents circN4BP2L2 as a key RNA shaping oncogenic phenotype in T-ALL.

Indexed as

Argonaute ProteinsBiomarkers, TumorPrecursor T-Cell Lymphoblastic Leukemia-LymphomaRNA, CircularApoptosisCell Line, TumorCell ProliferationGene Expression ProfilingGene Expression Regulation, LeukemicHumansMicroRNAsAGO2 protein, humanArgonaute ProteinsBiomarkers, TumorMicroRNAsRNA, Circular

Identifiers

PMID42509253
PMCPMC13612239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.